Welcome to Integrated Oncology

Home Page - Slider

Working with Integrated Oncology
Oncology Testing
VistaSeqSM Hereditary Cancer Testing
For Patients
working with integrated oncology
Working with Integrated Oncology

More than 25 years of testing
experience and expertise

Oncology Testing

Evolving personalize testing for you

Hereditary Cancer Testing

Because Knowledge is a Powerful Tool

for patients
For Patients

Dedicated to helping educate patients and inform the public
about oncology diagnostic testing.

For Patients

Prepare for visits with your doctor or a genetic counselor by learning about testing.

Working with Integrated Oncology

Integrated Oncology Highlights

This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). 

This test was recently FDA-approved as a complementary diagnostic test to help physicians determine which patients may benefit most with OPDIVO® (nivolumab). 

VistaSeqSM Hereditary Cancer Panel - an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.

This test was recently FDA-approved as a complementary diagnostic assay that may help identify patients with locally advanced or metastatic urothelial carcinoma more likely to respond to treatment with TecentriqTM(atezolizumab).

Prosigna Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, is an FDA 510(k) cleared assay to assess a patient’s risk of distant recurrence of disease. 

IntelliGEN® Oncology Therapeutic Panel (NGS) assay provides an assessment of targetable mutations within a panel of cancer genes known to be involved in the development, progression and/or treatment of cancers.